Inactive Instrument

Theradiag

Equities

ALTER

FR0004197747

Theradiag SA Announces Revenue Results for the Six Months Ended June 30, 2022

July 18, 2022 at 01:30 am EDT

Theradiag SA announced revenue results for the six months ended June 30, 2022. For the period, the company reported revenue of €6,264,000, compared with €5,482,000 in the first half of 2021, giving growth of 14.3%.

Latest news about Theradiag

Biosynex: merger with Theradiag completed	Dec. 18	CF
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
Theradiag: improved first-half profitability	23-09-18	CF
Theradiag: 7% growth in half-year sales	23-07-17	CF
Theradiag SA Reports Audited Revenue Results for the Second Quarter and First Half Ended on June 30, 2023	23-07-17	CI
Theradiag SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Theradiag SA Announces Executive Changes	23-03-01	CI
Theradiag SA Announces Management Changes	23-03-01	CI
Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million.	23-01-30	CI
Biosynex: takeover bid reopened for Theradiag shares	23-01-18	CF
Theradiag: takeover bid reopened on January 18	23-01-17	CF
Theradiag: 2022 sales without surprises	23-01-16	CF
Biosynex: successful takeover bid for Theradiag	23-01-16	CF
Theradiag: over 2.8 million shares tendered to the takeover bid	23-01-16	CF
Theradiag: growth of nearly 10% in 2022	23-01-16	CF
Theradiag SA Announces Revenue Results for the Year Ended December 31, 2022	23-01-16	CI
Biosynex SA completed the acquisition of 40% stakes in Theradiag SA.	23-01-11	CI
French Diagnostics Company Biosynex Offers to Take Over Theradiag	22-09-23	MT
Biosynex SA bid to acquire remaining 74.93% stakes in Theradiag SA.	22-09-22	CI
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI
Theradiag SA Announces Revenue Results for the Six Months Ended June 30, 2022	22-07-18	CI
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics	22-06-08	CI
Theradiag Announces the Launch of ez-Track, A Point-Of-Care Testing Solution for Therapeutic Drug Monitoring	22-05-31	CI
THERADIAG Announces the Launch of Two New i-Tracker® Kits	22-05-19	CI
Theradiag Announces Executive Changes	22-05-06	CI

Chart Theradiag

Duration

Period

More charts

Company Profile

Theradiag develops, produces, and sells in vitro diagnostic kits for detecting auto-immune diseases, allergies, and infectious diseases. The group also offers theranostic tests for monitoring biotherapies and determining patient response to treatments applied. 54.6% of net sales are abroad.

Sector

More about the company